vs
FLAGSTAR BANK, NATIONAL ASSOCIATION（FLG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是FLAGSTAR BANK, NATIONAL ASSOCIATION的1.6倍（$772.1M vs $498.0M），Revvity净利率更高（12.7% vs 4.2%，领先8.5%），Revvity同比增速更快（5.9% vs 1.6%），过去两年Revvity的营收复合增速更高（9.0% vs -10.7%）
Flagstar银行是原总部位于美国密歇根州特洛伊的商业银行，成立于1987年，主营零售及商业银行业务、抵押贷款发放及各类金融服务。其控股公司于2022年12月被纽约社区银行收购，后者后将全部门店统一为Flagstar品牌，2024年更名为Flagstar Financial，2025年启动企业重组。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FLG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$498.0M
营收增速更快
RVTY
高出4.2%
1.6%
净利率更高
RVTY
高出8.5%
4.2%
两年增速更快
RVTY
近两年复合增速
-10.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $498.0M | $772.1M |
| 净利润 | $21.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 11.4% | 14.5% |
| 净利率 | 4.2% | 12.7% |
| 营收同比 | 1.6% | 5.9% |
| 净利润同比 | -38.1% | 3.9% |
| 每股收益（稀释后） | $0.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FLGRVTY
| Q1 26 | $498.0M | — | ||
| Q4 25 | $2.1B | $772.1M | ||
| Q3 25 | $425.0M | $698.9M | ||
| Q2 25 | $419.0M | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | $461.0M | $729.4M | ||
| Q3 24 | $510.0M | $684.0M | ||
| Q2 24 | $557.0M | $691.7M |
净利润FLGRVTY
| Q1 26 | $21.0M | — | ||
| Q4 25 | $29.0M | $98.4M | ||
| Q3 25 | $-36.0M | $46.7M | ||
| Q2 25 | $-70.0M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | $-188.0M | $94.6M | ||
| Q3 24 | $-280.0M | $94.4M | ||
| Q2 24 | $-323.0M | $55.4M |
毛利率FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率FLGRVTY
| Q1 26 | 11.4% | — | ||
| Q4 25 | — | 14.5% | ||
| Q3 25 | -9.6% | 11.7% | ||
| Q2 25 | -19.3% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | -51.6% | 16.3% | ||
| Q3 24 | -65.7% | 14.3% | ||
| Q2 24 | -76.1% | 12.4% |
净利率FLGRVTY
| Q1 26 | 4.2% | — | ||
| Q4 25 | 1.4% | 12.7% | ||
| Q3 25 | -8.5% | 6.7% | ||
| Q2 25 | -16.7% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | -40.8% | 13.0% | ||
| Q3 24 | -54.9% | 13.8% | ||
| Q2 24 | -58.0% | 8.0% |
每股收益（稀释后）FLGRVTY
| Q1 26 | $0.03 | — | ||
| Q4 25 | $0.05 | $0.86 | ||
| Q3 25 | $-0.11 | $0.40 | ||
| Q2 25 | $-0.19 | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | $-1.11 | $0.77 | ||
| Q3 24 | $-0.79 | $0.77 | ||
| Q2 24 | $-1.14 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.1B | $7.3B |
| 总资产 | $87.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | $23.6B | $931.4M | ||
| Q2 25 | $22.9B | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $25.8B | $1.2B | ||
| Q3 24 | $33.6B | $1.2B | ||
| Q2 24 | $29.5B | $2.0B |
总债务FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $13.2B | — | ||
| Q2 25 | $13.2B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.4B | — | ||
| Q3 24 | $20.3B | — | ||
| Q2 24 | $28.9B | — |
股东权益FLGRVTY
| Q1 26 | $8.1B | — | ||
| Q4 25 | $8.1M | $7.3B | ||
| Q3 25 | $8.1B | $7.4B | ||
| Q2 25 | $8.1B | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $8.2B | $7.7B | ||
| Q3 24 | $8.6B | $7.9B | ||
| Q2 24 | $8.4B | $7.9B |
总资产FLGRVTY
| Q1 26 | $87.1B | — | ||
| Q4 25 | $87.5M | $12.2B | ||
| Q3 25 | $91.7B | $12.1B | ||
| Q2 25 | $92.2B | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $100.2B | $12.4B | ||
| Q3 24 | $114.4B | $12.8B | ||
| Q2 24 | $119.1B | $13.4B |
负债/权益比FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.63× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.37× | — | ||
| Q2 24 | 3.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $182.0M | ||
| Q3 25 | $243.0M | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $623.0M | $174.2M | ||
| Q3 24 | $-1.0B | $147.9M | ||
| Q2 24 | $796.0M | $158.6M |
自由现金流FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M |
自由现金流率FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% |
资本支出强度FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% |
现金转化率FLGRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FLG
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
